AIP Therapeutics

AIP Therapeutics is a South Korean biotechnology company specializing in the development of small molecule therapeutics that target the Aryl Hydrocarbon Receptor (AhR) pathway. The company's research focuses on the AIP-AhR axis to modulate immune responses, offering potential treatments for both oncology and autoimmune diseases. Their lead candidate, AIP-101, is an AhR agonist currently in clinical development for the treatment of atopic dermatitis. By leveraging deep expertise in protein-protein interactions within the AhR complex, AIP Therapeutics seeks to address significant unmet needs in immunology and oncology through precision modulation of immune homeostasis.